去氢钩藤碱
中文名称 | 去氢钩藤碱 |
---|---|
中文同义词 | CORYNOXEINE 去氢钩藤碱;柯诺辛因碱;去氢钩藤碱(标准品);去氢钩藤碱(柯诺辛因碱);去氢钩藤碱;去氢钩藤碱?, 99.9%;ERK1/2抑制剂(CORYNOXEINE);化合物KARTOGENIN |
英文名称 | corynoxeine |
英文同义词 | corynoxeine;(7R,16E,20α)-16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;(alphaE,1'R,6'R,7'S,8'aS)-6'-Ethenyl-1,2,2',3',6',7',8',8'a-octahydro-alpha-(methoxymethylene)-2-oxospiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid methyl ester;16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-aceticacid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-a-(methoxymethylene)-2-oxo-, methyl ester, (aE,1'R,6'R,7'S,8'aS)-;Corynoxeine, 99.9%;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-α-(methoxymethylene)-2-oxo-, methyl ester, (αE,1'R,6'R,7'S,8'aS)-;corynoxeine USP/EP/BP |
CAS号 | 630-94-4 |
分子式 | C22H26N2O4 |
分子量 | 382.46 |
EINECS号 | |
相关类别 | 中药对照品;标准品;对照品,标准品;植物提取物;中草药成分;对照品;植提标准品;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;分析试剂标准品;细胞生物学试剂;标准品-中药标准品;标准品 -中药标准品;标准品,对照品 |
Mol文件 | 630-94-4.mol |
结构式 |
去氢钩藤碱 性质
熔点 | 210℃ |
---|---|
沸点 | 562.7±50.0 °C(Predicted) |
密度 | 1.25 |
溶解度 | DMSO:27.87(最大浓度 mg/mL);72.87(最大浓度 mM) |
酸度系数(pKa) | 13.54±0.60(Predicted) |
形态 | 粉末 |
颜色 | 白色至米白色 |
ERK1
|
ERK2
|
Corynoxeine is able to inhibit the PDGF-BB-stimulated proliferation of VSMCs through downregulation of PDGF-BB-induced ERK1/2 activation. Pre-incubation of VSMCs with Corynoxeine significantly inhibits PDGF-BB-induced extracellular signal-regulated kinase 1/2 (ERK1/2) activation, whereas Corynoxeine has no effects on mitogen-activated protein kinase (MAPK/ERK)-activating kinase 1 and 2 (MEK1/2), Akt, or phospholipase C (PLC) γ 1 activation or on PDGF receptor beta (PDGF-Rβ) phosphorylation. Corynoxeine inhibits PDGF-BB-induced ERK1/2 activation, in the same concentration range that inhibits VSMC proliferation and DNA synthesis. Corynoxeine inhibits VSMC numbers in response to PDGF-BB with 50% inhibitory concentrations (IC 50 ) of 13.7 μM. Corynoxeine inhibits DNA synthesis in response to PDGF-BB (24 h) with IC 50 of 9.2 μM. Pre-treatment of VSMCs with Corynoxeine (5-50 μM) for 24 h results in significant decreases in cell number without any cytotoxicity; the inhibition percentages are 25.0±12.5, 63.0±27.5 and 88.0±12.5% at 5, 20 and 50 μM, respectively. Corynoxeine also significantly inhibits the 50 ng/mL PDGF-BB-induced DNA synthesis of VSMCs in a concentration-dependent manner without any cytotoxicity; the inhibitions are 32.8±11.0, 51.8±8.0 and 76.9±7.4% at concentrations of 5, 20 and 50 μM, respectively.
药理药效:本品有抑制呼吸中枢和离体肠管及兴奋大鼠离体子宫,降低血压,抗血小板聚集并有促进已聚集血小板解聚的作用。还能改善红细胞的变形能力,抑制不良因素对红细胞变形能力的损害。临床用于治疗高血压病,对I、II期高血压有一定的疗效。
安全信息
海关编码 | 2933998090 |
---|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-N0590 | Corynoxeine | 1 mg | 628元 | |
2024/08/19 | HY-N0590 | 去氢钩藤碱 Corynoxeine | 630-94-4 | 5mg | 700元 |